Patrick Mooney, Chief Executive Officer

Patrick Mooney was appointed CEO of SpyGlass Pharma in July 2021. He brings over 24 years of experience in ophthalmology, having held leadership positions at prominent companies. Prior to joining SpyGlass Pharma, he served as Vice President and Head of Novartis Ophthalmics at Novartis from 2017 to 2021 and as Director of Sales and Senior Director of Commercial Development at Galderma from 2015 to 2017. He also spent 16 years at Alcon, where he held various leadership roles in sales, marketing, and operations. Mr. Mooney has been instrumental in leading several launches and commercialization efforts for ophthalmic pharmaceuticals and medical devices. SpyGlass Pharma, previously a privately held company, secured significant Series C and D financing from venture capital firms such as RA Capital Management, New Enterprise Associates, and Sands Capital, indicating a history of managing companies backed by private equity-like investments.

Jean-Frédéric Viret, Ph.D., Chief Financial Officer

Jean-Frédéric Viret was appointed Chief Financial Officer of SpyGlass Pharma in January 2026. He possesses over 20 years of corporate finance experience within the life sciences sector, guiding companies through various stages from early-stage clinical development to commercialization and post-commercial growth. Dr. Viret's prior roles include serving as Chief Financial Officer for NGM Biopharmaceuticals, Inc., Blade Therapeutics, Inc., and Coherus BioSciences, Inc. (NASDAQ: CHRS), a commercial-stage biopharmaceutical company. His extensive background spans CFO positions at multiple public and privately held biopharmaceutical and diagnostics companies.

Malik Y. Kahook, M.D., Co-Founder, President and Executive Chairman

Dr. Malik Y. Kahook co-founded SpyGlass Pharma in 2019 with Glenn Sussman. He is a glaucoma and cataract surgeon and serves as a professor and Vice Chair of Translational Research at the University of Colorado. Dr. Kahook established a glaucoma service and a medical device innovations lab that led to the commercialization of several medical devices and subsequently the creation of SpyGlass Pharma. He also holds the titles of President and Executive Chairman of the Board.

Glenn Sussman, Co-Founder and Chief Technology Officer

Glenn Sussman co-founded SpyGlass Pharma in 2019 alongside Dr. Malik Y. Kahook. He previously served as the CEO of SpyGlass Pharma before being appointed Chief Technology Officer, where he continues to oversee technical development. Mr. Sussman is a medical device engineer and product development leader, bringing over 15 years of collaborative expertise with Dr. Kahook to the company.

Chetan Pujara, Ph.D., Chief Research & Development Officer

Dr. Chetan Pujara was appointed Chief Research & Development Officer of SpyGlass Pharma in March 2025. He has over 20 years of leadership experience in the development of pharmaceutical and drug-device combination products across various therapeutic areas, including ophthalmic, neurological, and dermatological. Dr. Pujara has led global organizations that contributed to the development of several market-leading products, such as Ozurdex®, Durysta™, and Latisse®. Before joining SpyGlass Pharma, he held key leadership roles at Abbott, Allergan, AbbVie, and served as Chief Development Officer at Osanni.

Key Risks to SpyGlass Pharma

1. Clinical Development and Regulatory Approval Risk: SpyGlass Pharma's lead product candidate, the BIM-IOL System, is currently undergoing pivotal Phase 3 clinical trials. As a late-stage biopharmaceutical company, its future success and ability to generate revenue are highly dependent on the successful completion of these trials and the subsequent receipt of regulatory approvals from authorities like the FDA. There is an inherent risk that clinical trials may not demonstrate sufficient efficacy or safety, or that regulatory bodies may not grant approval for commercialization.
2. Commercialization and Market Adoption Risk: Even upon successful regulatory approval, SpyGlass Pharma will face challenges in the commercialization and market adoption of its products. The company's ability to successfully launch the BIM-IOL System, gain acceptance among ophthalmologists and cataract surgeons, and secure favorable reimbursement pathways in a competitive ophthalmic market are critical for its financial viability.
3. Intellectual Property and Litigation Risk: The company is involved in a "trade secret dispute with local rival Glaukos Corp.". Such intellectual property disputes can lead to costly litigation, divert management's attention and resources, and potentially impact the company's ability to commercialize its products, thus posing a significant risk to the business.

SpyGlass Pharma (NASDAQ: SGP) primarily focuses on developing sustained drug delivery solutions for chronic eye conditions, with its lead product being the Bimatoprost Drug Pad-Intraocular Lens System (BIM-IOL System).

The estimated total addressable market for SpyGlass Pharma's BIM-IOL System is approximately $13 billion in the U.S. This market specifically targets glaucoma and ocular hypertension patients who are undergoing cataract surgery.

SpyGlass Pharma (SGP) is a late-stage biopharmaceutical company focused on developing long-acting, sustained drug delivery solutions for chronic eye conditions. Over the next 2-3 years, several key drivers are expected to fuel the company's revenue growth:

1. Successful Clinical Development and Commercial Launch of the BIM-IOL System: SpyGlass Pharma's primary revenue growth driver is the advancement and eventual commercialization of its lead product candidate, the Bimatoprost Drug Pad–Intraocular Lens System (BIM-IOL System). This system is designed for implantation during routine cataract surgery to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company recently announced positive 12-month results from its Phase 1/2 trial, demonstrating significant intraocular pressure reduction and a high rate of patients discontinuing topical IOP-lowering medications. Proceeds from its recent initial public offering (IPO) in February 2026 are primarily allocated to completing two registrational Phase 3 clinical trials, initiated in July 2025, and subsequently funding the commercial launch of the BIM-IOL System if approved.
2. Penetration of the Large Addressable Market for Glaucoma and Cataract Patients: The BIM-IOL System targets a substantial market opportunity, with SpyGlass Pharma estimating a $13 billion U.S. market for glaucoma and ocular hypertension patients undergoing cataract surgery. With approximately 5 million U.S. cataract surgeries expected in 2025 and an annual growth rate of 3-4%, the company aims to capture a significant share by integrating long-acting glaucoma therapy into a routine surgical procedure, thereby addressing adherence issues associated with daily eye drops.
3. Advancement and Potential Commercialization of the BIM-DRS: Beyond its lead candidate, SpyGlass Pharma is also developing the BIM-DRS, a second product candidate aimed at glaucoma patients who are not undergoing cataract surgery. The successful development and eventual commercialization of BIM-DRS would expand the company's market reach beyond cataract patients, providing a broader solution for glaucoma management.
4. Leveraging the Proprietary SpyGlass Platform for New Indications: The company's underlying non-bioerodible SpyGlass Platform is a versatile drug delivery technology designed to work with various approved medicines, including bimatoprost and other small molecules. This platform offers flexibility to potentially treat a range of conditions in both the front and back of the eye. Future revenue growth could be driven by applying this platform to develop new products for additional ophthalmic indications, diversifying its product pipeline and expanding its therapeutic footprint.

Share Issuance

• SpyGlass Pharma completed its Initial Public Offering (IPO) on February 6, 2026, with shares beginning to trade on the Nasdaq Global Select Market under the ticker symbol SGP.
• The company sold 10,781,250 shares of common stock at a public offering price of $16.00 per share.
• This offering, which included the full exercise of the underwriters' option to purchase additional shares, generated aggregate gross proceeds of $172.5 million.

Inbound Investments

• Prior to its IPO, Gilde Healthcare participated in a Series D financing round for SpyGlass Pharma in June 2025.